STAMPEDE: is radiation therapy to the primary a new standard of care in men with metastatic prostate cancer?
Affiliation
Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2019
Metadata
Show full item recordCitation
Choudhury A, Chen RC, Henry A, Mistry H, Mitin T, Pinkawa M, et al. STAMPEDE: is radiation therapy to the primary a new standard of care in men with metastatic prostate cancer? Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):33-5.Journal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2018.12.040PubMed ID
30967237Additional Links
https://dx.doi.org/10.1016/j.ijrobp.2018.12.040Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2018.12.040
Scopus Count
Collections
Related articles
- Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
- Authors: Messina C, Messina M, Boccardo F
- Issue date: 2018 Jan
- Treatment of hormone-naïve metastatic prostate cancer.
- Authors: Hamilou Z, Saad F, Fizazi K
- Issue date: 2018 Sep
- Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
- Authors: Ranasinghe WKB, Reichard CA, Chapin BF
- Issue date: 2019 Nov
- The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
- Authors: Sundahl N, Tree A, Parker C
- Issue date: 2020 Jan 20
- Metastatic Prostate Cancer.
- Authors: Sartor O, de Bono JS
- Issue date: 2018 Feb 15